{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:10:20Z","timestamp":1787155820005,"version":"build-2736575974"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060235"],"award-info":[{"award-number":["82060235"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The clinical spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is expanding over time. However, the long-term management and prognosis of this disorder are still controversial. Therefore, this study aimed to report the clinical profiles and treatment outcomes of MOGAD in our center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single-center case-series study. Clinical and para-clinical data, along with treatment outcomes of patients with MOGAD were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 27 patients were identified, of which 19 (70%) patients were women, and the median age at disease onset was 40 years (range 20\u201367). A total of 47 episodes were observed, with optic neuritis (53%) being the most frequent presentation and 60% of them were unilateral. Other presentations included rhombencephalitis (RE) (17%), limbic encephalitis (9%), simultaneous optic neuritis and myelitis (9%), acute disseminated encephalomyelitis (ADEM)-like presentation (6%), myelitis (4%), and ADEM (2%). One patient presenting with RE also met the diagnostic criteria of area postrema syndrome (APS). Another patient with RE presented with imaging characteristics of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). A total of 29 lumbar punctures were recorded, among which an elevated protein level was found in 34% of the samples, pleocytosis was found in 14% of the samples, and positive intrathecal oligoclonal bands were found in 19% of the patients. One patient was found to have anti-N-methyl-D-aspartate receptor antibodies both in his serum and cerebrospinal fluid. Intravenous methylprednisolone (IVMP) was administrated for 85% of the attacks while both IVMP and intravenous immunoglobulin were for 6% of the attacks. Moreover, nine patients received maintenance therapy. Among them, six patients were treated with mycophenolate mofetil, three patients were treated with prednisone, rituximab, and teriflunomide, respectively. The median follow-up period was 20 months (range 6\u2013127). At follow-up, twelve (44%) patients experienced a relapsing course, and the median time to the first relapse was 9.5 months (range 2\u2013120). The median Expanded Disability Status Scale score at nadir was 3.5 (range 2\u20138) and was 0 (range 0\u20133) at the last follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The clinical spectrum of MOGAD is heterogenous, wherein APS and CLIPPERS-form can occur. The long-term outcome of MOGAD seems benign. Further studies are warranted to determine the risk factors of relapse and identify the optimal steroid-sparing agents.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.830488","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T04:28:18Z","timestamp":1649219298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Profile and Treatment Outcome in MOGAD: A Single-Center Case-Series Study in Guiyang, China"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoyang","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Reindl","year":"2021","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"102308","DOI":"10.1016\/j.msard.2020.102308","article-title":"Anti-myelin oligodendrocyte glycoprotein (MOG) associated disease masquerading as prolonged intractable nausea and vomiting","volume":"44","author":"Block","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1111\/ene.13483","article-title":"CLIPPERS mimickers: relapsing brainstem encephalitis associated with anti-MOG antibodies","volume":"25","author":"Berzero","year":"2018","journal-title":"Eur J Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/ene.13790","article-title":"Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China","volume":"26","author":"Wang","year":"2019","journal-title":"Eur J Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e924","DOI":"10.1212\/NXI.0000000000000924","article-title":"Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders","volume":"8","author":"Rinaldi","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1642","DOI":"10.1212\/WNL.0000000000006392","article-title":"Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD","volume":"91","author":"Shosha","year":"2018","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1093\/brain\/awx200","article-title":"Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS)","volume":"140","author":"Tobin","year":"2017","journal-title":"Brain."},{"key":"B11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain."},{"key":"B13","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3389\/fneur.2020.00396","article-title":"Value of area postrema syndrome in differentiating adults with AQP4 vs. MOG antibodies","volume":"11","author":"Hyun","year":"2020","journal-title":"Front Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement-frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation."},{"key":"B15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1212\/WNL.0000000000008786","article-title":"Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)?","volume":"94","author":"Kunchok","year":"2020","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2214\/AJR.20.24061","article-title":"MOGAD: how it differs from and resembles other neuroinflammatory disorders","volume":"216","author":"Shahriari","year":"2021","journal-title":"AJR Am J Roentgenol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1212\/WNL.0000000000001370","article-title":"Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS","volume":"84","author":"Symmonds","year":"2015","journal-title":"Neurology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"102874","DOI":"10.1016\/j.msard.2021.102874","article-title":"\u201cPeppering the pons\u201d: CLIPPERS or myelin oligodendrocyte glycoprotein associated disease?","volume":"51","author":"Obeidat","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1136\/jnnp-2020-325759","article-title":"Primary CNS lymphoma after CLIPPERS: a case series","volume":"92","author":"Doubrovinskaia","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jns.2014.06.015","article-title":"A central nervous system B-cell lymphoma arising two years after initial diagnosis of CLIPPERS","volume":"344","author":"Taieb","year":"2014","journal-title":"J Neurol Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2013.2016","article-title":"Fatal B-cell lymphoma following chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids","volume":"70","author":"De Graaff","year":"2013","journal-title":"JAMA Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J Neuroinflammation."},{"key":"B23","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1177\/1352458520933884","article-title":"Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD","volume":"27","author":"Kunchok","year":"2021","journal-title":"Mult Scler."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1177\/1352458520951046","article-title":"MOG-IgG1 and co-existence of neuronal autoantibodies","volume":"27","author":"Kunchok","year":"2021","journal-title":"Mult Scler."},{"key":"B25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.msard.2018.01.007","article-title":"Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis","volume":"20","author":"Fan","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"711376","DOI":"10.3389\/fneur.2021.711376","article-title":"Clinical features of coexisting Anti-NMDAR and MOG antibody-associated encephalitis: a systematic review and meta-analysis","volume":"12","author":"Ding","year":"2021","journal-title":"Front Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/ene.14746","article-title":"The long-term outcome of MOGAD: An observational national cohort study of 61 patients","volume":"28","author":"Deschamps","year":"2021","journal-title":"Eur J Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"117088","DOI":"10.1016\/j.jns.2020.117088","article-title":"Unfavorable outcome in highly relapsing MOGAD encephalitis","volume":"418","author":"Buciuc","year":"2020","journal-title":"J Neurol Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"103229","DOI":"10.1016\/j.msard.2021.103229","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: the difficulty of predicting relapses","volume":"56","author":"Epstein","year":"2021","journal-title":"Mult Scler Relat Disord."},{"key":"B32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with Myelin Oligodendrocyte Glycoprotein Autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation."},{"key":"B34","article-title":"Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany","volume-title":"J Neurol Neurosurg Psychiatry.","author":"Liu","year":"2020"},{"key":"B35","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","article-title":"Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases","volume":"88","author":"Hyun","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial Anti-Myelin Oligodendrocyte Glycoprotein antibody analyses and outcomes in children with Demyelinating Syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1136\/practneurol-2017-001787","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations","volume":"19","author":"Jury\u0144czyk","year":"2019","journal-title":"Pract Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.830488\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T04:28:21Z","timestamp":1649219301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.830488\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":38,"alternative-id":["10.3389\/fneur.2022.830488"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.830488","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]},"article-number":"830488"}}